Furthermore, tapinarof exhibits direct binding to the aryl hydrocarbon receptor (AhR), leading to a reduction in the production of inflammatory cytokines, including IL-17A, IL-17F, IL-22, IL-23, and IL-1β, as demonstrated in a psoriasis-like mouse model (Smith et al., 2017b). This evidence concerns the gene IL17A and psoriasis.